Abstract
In ASPREE, we previously reported a surprising increase in cancer-related deaths associated with initiating aspirin. We now report primary incident cancer events. Aspirin was not associated with risk of incident cancer (HR=1.04, 95% CI 0.95-1.14), including non-metastatic cancer (HR=0.99, 95% CI, 0.89-1.11) and colorectal cancer (HR=1.02; 95% CI, 0.81-1.30). However, risk of incident metastatic cancer was elevated with aspirin (HR=1.18; 95% CI,0.96-1.46), although this could be attributable to chance. In ASPREE, the increase in cancer deaths associated with initiation of aspirin was not accompanied by a significant increase in overall incident cancer after 4.7 years. However, there did appear to be an increase in the incidence of advanced cancer in the aspirin arm. These data support the possibility that aspirin may adversely affect short-term outcomes among elderly participants with undiagnosed cancers (e.g. prevalent tumors at enrollment or early incident tumors) and/or may have differential effects according to age.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.